Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/193597| Title: | Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests |
| Author: | Saponaro, Mariarosaria Annunziata, Luigi Turla, Antonella Viganò, Ilaria Laurentiis, Michele De Giuliano, Mario Mastro, Lucia del Montemurro, Filippo Puglisi, Fabio Angelis, Carmine De Buono, Giuseppe Schettini, Francesco Arpino, Grazia |
| Keywords: | Càncer de mama Tractament adjuvant del càncer Hormonoteràpia Receptors d'hormones Genòmica Efectes secundaris Breast cancer Adjuvant treatment of cancer Hormone therapy Hormone receptors Genomics Side effects |
| Issue Date: | 6-Nov-2022 |
| Publisher: | MDPI |
| Abstract: | In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice. |
| Note: | Reproducció del document publicat a: https://doi.org/10.3390/ijms232113604 |
| It is part of: | International Journal of Molecular Sciences, 2022, vol. 23, num. 21, p. 13604 |
| URI: | http://hdl.handle.net/2445/193597 |
| Related resource: | https://doi.org/10.3390/ijms232113604 |
| ISSN: | 1661-6596 |
| Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 729774.pdf | 314.22 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
